Abemaciclib: all 171 studies that test it

Page 2 of 2. Open to participants first (62), then studies with results posted, then the rest; newest registration first within each.

• A Study of Abemaciclib in Healthy ParticipantsCompletedNCT02672423Phase 1Results posted
• A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without FoodCompletedNCT02482935Phase 1Results posted
• A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung CancerCompletedNCT02450539Phase 2Results posted
• A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast CancerCompletedNCT02441946Phase 2Results posted
• A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02411591Phase 1Results posted
• A Study of Abemaciclib in Participants With Varying Degrees of Liver ImpairmentCompletedNCT02387814Phase 1Results posted
• A Study of LY2835219 in Healthy ParticipantsCompletedNCT02327143Phase 1Results posted
• A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the BrainCompletedNCT02308020Phase 2Results posted
• A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast CancerActive, not recruitingNCT02246621Phase 3Results posted
• A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung CancerActive, not recruitingNCT02152631Phase 3Results posted
• A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerActive, not recruitingNCT02107703Phase 3Results posted
• A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has SpreadCompletedNCT02102490Phase 2Results posted
• A Study of LY2835219 in Healthy ParticipantsCompletedNCT02059148Phase 1Results posted
• A Study of LY2835219 in Japanese Participants With Advanced CancerCompletedNCT02014129Phase 1Results posted
• A Study of Carbon-14-Labeled LY2835219 ([^14C]-LY2835219) in Healthy ParticipantsCompletedNCT01913314Phase 1Results posted
• Study of LY2835219 for Mantle Cell LymphomaCompletedNCT01739309Phase 2Results posted
• A Phase 1 Study of LY2835219 In Participants With Advanced CancerCompletedNCT01394016Phase 1Results posted
• Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in EgyptCompletedNCT07487129Phase 4
• ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast CancerCompletedNCT06570031Phase 1
• A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following RadiotherapyActive, not recruitingNCT06413706Phase 2
• Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial TreatmentTerminatedNCT05999968Phase 1
• A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationActive, not recruitingNCT05708235Phase 2
• Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 GenotypeWithdrawnNCT05691400Phase 4
• TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)Active, not recruitingNCT05548127Phase 1/2
• Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast CancerTerminatedNCT05065411Phase 3
• SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated LiposarcomaActive, not recruitingNCT04967521Phase 3
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingNCT04931342Phase 2
• Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)Active, not recruitingNCT04862663Phase 3
• Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicable
• Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast CancerTerminatedNCT04791384Phase 1/2
• LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal CancerActive, not recruitingNCT04616183Phase 1/2
• ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaLCompletedNCT04603183Phase 2
• CDK4/6 Tumor, Abemaciclib, PaclitaxelCompletedNCT04594005Phase 1/2
• Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain MetastasesWithdrawnNCT04585724Phase 1
• PreOperative Endocrine Therapy for Individualised Care With AbemaciclibActive, not recruitingNCT04584853Phase 3
• Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBCActive, not recruitingNCT04565054Phase 3
• Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib ResistanceActive, not recruitingNCT04545710Phase 2
• A Study of ZN-c5 and Abemaciclib in Participants With Breast CancerCompletedNCT04514159Phase 1
• Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast CancerCompletedNCT04481113Phase 1
• Abemaciclib and Letrozole to Treat Endometrial CancerActive, not recruitingNCT04393285Phase 2
• LY3214996 Plus Abemaciclib in Recurrent Glioblastoma PatientsCompletedNCT04391595Early Phase 1
• T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast CancerWithdrawnNCT04351230Phase 2
• Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate CancerWithdrawnNCT04272645Phase 2
• Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)TerminatedNCT04227327Phase 2
• Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade GliomaWithdrawnNCT04220892Early Phase 1
• Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast CancerActive, not recruitingNCT04158362Phase 3
• Abemaciclib + Pembrolizumab In GlioblastomaWithdrawnNCT04118036Phase 2
• Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast CancerWithdrawnNCT04088032Early Phase 1
• Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6TerminatedNCT04074785Early Phase 1
• A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced CancerCompletedNCT04071262Phase 1
• Abemaciclib and Letrozole in Treating Patients With Endometrial CancerCompletedNCT04049227Early Phase 1
• Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLCCompletedNCT04010357Phase 2
• Genetic Testing in Guiding Treatment for Patients With Brain MetastasesActive, not recruitingNCT03994796Phase 2
• A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast CancerWithdrawnNCT03988114Phase 4
• Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast CancerTerminatedNCT03979508Phase 2
• A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell CarcinomaTerminatedNCT03905889Phase 1
• Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine TumorsActive, not recruitingNCT03891784Phase 2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Tucatinib + Abemaciclib + Herceptin for HER2+ MBCWithdrawnNCT03846583Phase 1
• (CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial CancerActive, not recruitingNCT03837821Early Phase 1
• Myeloma-Developing Regimens Using Genomics (MyDRUG)CompletedNCT03732703Phase 1/2
• Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active, not recruitingNCT03616587Phase 1
• Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous CarcinomaActive, not recruitingNCT03531645Phase 2
• A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based TherapyStatus unknownNCT03356587Phase 2
• Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6CompletedNCT03356223Phase 2
• Multiorgan Metabolic Imaging Response Assessment of AbemaciclibCompletedNCT03339843Phase 2
• Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]CompletedNCT03292250Phase 2
• Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain TumorsActive, not recruitingNCT03220646Phase 2
• Study of Abemaciclib in Dedifferentiated LiposarcomaActive, not recruitingNCT02846987Phase 2
• Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib (LY2835219) in Early Breast Cancer PatientsCompletedNCT02831530Phase 2
• Abemaciclib in Children With DIPG or Recurrent/Refractory Solid TumorsCompletedNCT02644460Phase 1

← Abemaciclib overview